Technical Analysis for ICAD - icad inc.

Grade Last Price % Change Price Change
F 1.49 4.20% 0.06
ICAD closed up 4.2 percent on Thursday, May 2, 2024, on 40 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 15
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 4.20%
Oversold Stochastic Weakness 4.20%
NR7 Range Contraction 4.20%
NR7-2 Range Contraction 4.20%
Oversold Stochastic Weakness 4.20%
NR7 Range Contraction 0.68%
Inside Day Range Contraction 0.68%
Oversold Stochastic Weakness 0.68%
Gapped Up Strength 1.36%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 17 hours ago
Up 5% about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Rose Above 10 DMA about 18 hours ago
Possible NR7 about 18 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

icad inc. Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy that enable healthcare professionals and radiologists to identify pathologies and pinpoint cancer earlier. It offers Axxent eBx system, which is used for the treatment of early stage breast cancer, endometrial cancer, and skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated. It also provides computer-aided detection (CAD) solutions for digital and film-based mammography systems, including SecondLook systems that detects and identifies masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to PACS and/or review workstations. In addition, the company offers image analysis and workflow solutions in MRI imaging comprising SpectraLook for breast, VividLook for prostate, and OmniLook for other organs; and VersaVue Enterprise, a review and reporting solution, which provides visual and quantitative depictions of the movement of contrast agent through a lesion. Further, it provides VeraLook that supports the detection of colonic polyps in conjunction with CT Colonography; and the TotalLook MammoAdvantage system, a mammography specific digitizer. The company sells its products to hospitals, ambulatory care centers, and free standing radiation oncology facilities. It sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.


Classification

Sector: Technology
Industry: Software - Application
Keywords: Medicine Cancer Imaging Breast Cancer Radiation Treatment Of Breast Cancer Medical Imaging Radiation Therapy Polyp MRI Organs Workflow Solutions Cancer Screening Endometrial Cancer Skin Cancer Mammography Ambulatory Care Picture Archiving And Communication System Breast Imaging

Is ICAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.97
52 Week Low 1.05
Average Volume 213,881
200-Day Moving Average 1.80
50-Day Moving Average 1.64
20-Day Moving Average 1.57
10-Day Moving Average 1.50
Average True Range 0.13
RSI (14) 44.44
ADX 19.49
+DI 18.69
-DI 17.26
Chandelier Exit (Long, 3 ATRs) 1.61
Chandelier Exit (Short, 3 ATRs) 1.78
Upper Bollinger Bands 1.77
Lower Bollinger Band 1.38
Percent B (%b) 0.28
BandWidth 24.71
MACD Line -0.05
MACD Signal Line -0.04
MACD Histogram -0.0134
Fundamentals Value
Market Cap 39.27 Million
Num Shares 26.4 Million
EPS -0.49
Price-to-Earnings (P/E) Ratio -3.04
Price-to-Sales 1.44
Price-to-Book 1.18
PEG Ratio -0.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.63
Resistance 3 (R3) 1.62 1.58 1.60
Resistance 2 (R2) 1.58 1.54 1.58 1.59
Resistance 1 (R1) 1.53 1.52 1.56 1.54 1.59
Pivot Point 1.49 1.49 1.50 1.49 1.49
Support 1 (S1) 1.44 1.45 1.47 1.45 1.39
Support 2 (S2) 1.40 1.43 1.40 1.39
Support 3 (S3) 1.35 1.40 1.38
Support 4 (S4) 1.36